Media reports about psychedelics are now more likely to be about emerging therapeutic uses than about raves or drug busts. Are your clients asking you about them, are you curious about their potential to enliven psychotherapy? Clinical trials of MDMA and psilocybin as catalysts to psychotherapy are in final stages of FDA trials. Results show large treatment effects for PTSD, depression, and relationship satisfaction in couples. In this treatment model, the drugs are administered only a few times in a course of psychotherapy aimed at accessing the individual’s own healing potential. Guided in this recording by the psychiatrist at the helm of the MDMA-assisted psychotherapy trials, you’ll explore:
This online program is worth 4 hours CPD.
|Manual - Emerging Psychedelic Treatments (12.7 MB)||119 Pages||Available after Purchase|
Michael Mithoefer, MD, clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.
Financial: Dr. Michael Mithoefer has employment relationships with the Medical University of South Carolina and the Multidisciplinary Association for Psychedelic Studies. He has an ownership interest in Awakn Life Sciences and serves on the scientific advisory board. Dr. Mithoefer receives a speaking honorarium and recording royalties from PESI, Inc.
Non-financial: Dr. Michael Mithoefer is a fellow of the American Psychiatric Association.
Rick Doblin, Ph.D., Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS); chair of the board of directors MAPS Public Benefit Corporation.
Financial: Richard Doblin has an employment relationship with Multidisciplinary Association for Psychedelic Studies, Inc. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Richard Doblin has no relevant non-financial relationships.
Access never expires for this product.
For a more detailed outline that includes times or durations of time, if needed, please contact email@example.com
Please wait ...